ChromaDex, Inc.
10005 Muirlands Boulevard
Suite G, First Floor
Irvine
California
92618
United States
Tel: 949-419-0288
Fax: 949-419-0294
Website: http://www.chromadex.com/
Email: custsvc@chromadex.com
246 articles about ChromaDex, Inc.
-
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
3/6/2024
ChromaDex Corp. announced fourth quarter and fiscal year 2023 financial results. Fourth Quarter 2023 and Recent Highlights Total net sales of $21.2 million, with $17.6 million from Tru Niagen®, up 1% and 9%, respectively, from the prior year quarter.
-
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
2/21/2024
ChromaDex Corp. announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter, which ended December 31, 2023.
-
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024
2/5/2024
ChromaDex Corp. announced today that it will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Monday, February 12, 2024, at 11:00 AM PST.
-
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®
11/30/2023
ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, shares results from a new breakthrough study analyzing the safety of high-dose nicotinamide riboside (NR) supplementation on individuals with Parkinson’s disease (PD).
-
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR)
11/15/2023
ChromaDex Corp. (NASDAQ:CDXC), one of the global authorities on Nicotinamide Adenine Dinucleotide (NAD + ) and healthy aging research, shares results from a phase II clinical study published in the peer-reviewed journal, Movement Disorders, by a team of researchers led by Dr. Hilde Nilsen, University of Oslo, Arkershus University Hospital, Norway.
-
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023
11/9/2023
ChromaDex Corporation announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, November 14, 2023, at 2:00 PM EDT.
-
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
11/8/2023
ChromaDex Corp. announced financial results for the third quarter of 2023.
-
Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN
8/24/2023
ChromaDex Corp. as reported in the peer-reviewed journal International Journal of Molecular Sciences by a team of scientists led by Dr. Yue Yang, Assistant Professor of Research in Pharmacology at Weill Cornell Medicine in New York.
-
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
8/9/2023
ChromaDex Corp. announced financial results for the second quarter of 2023.
-
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series
8/7/2023
ChromaDex Corp. announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Monday, August 14, 2023, at 12:00 p.m. ET (9:00 a.m. PT).
-
ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
8/2/2023
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, August 9, 2023 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended on June 30, 2023.
-
Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects
7/18/2023
ChromaDex Corp. announced promising findings from two independent clinical study abstracts originally presented this past April at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting.
-
ChromaDex to Participate in the LD Micro Invitational XIII
5/30/2023
ChromaDex Corp. (NASDAQ:CDXC) today announced that it will be participating at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023.
-
ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference
5/11/2023
ChromaDex Corp. today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2023 Investor Conference.
-
ChromaDex Corporation Reports First Quarter 2023 Financial Results
5/10/2023
ChromaDex Corp. announced financial results for the first quarter of 2023.
-
ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
5/2/2023
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, May 10, 2023 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2023.
-
ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor Space
2/22/2023
ChromaDex Corp., a global bioscience company dedicated to healthy aging, holds an exclusive license from Queen’s University Belfast for methods of making nicotinamide riboside and related derivatives, some of the most efficient nicotinamide adenine dinucleotide precursors, and announced it expanded this patent family with newly granted U.S. Patent 11,584,770 for purity compositions of dihydronicotinamide riboside and dihydronicotinic acid riboside.
-
ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients
1/31/2023
ChromaDex Corp. announced promising findings from a first-of-its kind clinical study, as reported in the peer-reviewed journal Translational Neurodegeneration by a team of scientists led by Dr. Adil Mardinoglu.
-
ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)
1/12/2023
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has appointed Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc. to its Scientific Advisory Board (SAB).
-
ChromaDex Named Brianna Gerber Chief Financial Officer
1/5/2023
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it has appointed Brianna Gerber to the role of Chief Financial Officer, effective January 1, 2023.